| Garrett James Nelson, MD | |
|
9601 Baptist Health Dr Ste 690, Little Rock, AR 72205-6328 | |
| (501) 227-8422 | |
| Not Available |
| Full Name | Garrett James Nelson |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 12 Years |
| Location | 9601 Baptist Health Dr Ste 690, Little Rock, Arkansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295098440 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | E9601 (Arkansas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prime Medical Group Pllc | 1153753520 | 16 |
News Archive
Sequencing technology has advanced significantly since the race to sequence the human genome first began. As part of the Teagasc Vision Programme a 'next generation sequencer', the only one of its kind in Ireland, was installed at Teagasc Food Research Centre, Moorepark.
TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that discussions with 3M continue, with the intent of signing a definitive agreement which would provide 3M with a global license and distribution rights to TSO3's STERIZONE 125L sterilizer including new cycles recently announced by TSO3.
Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
› Verified 5 days ago
| Entity Name | Johnson Dermatology Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437110962 PECOS PAC ID: 4789688615 Enrollment ID: O20060908000043 |
News Archive
Sequencing technology has advanced significantly since the race to sequence the human genome first began. As part of the Teagasc Vision Programme a 'next generation sequencer', the only one of its kind in Ireland, was installed at Teagasc Food Research Centre, Moorepark.
TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that discussions with 3M continue, with the intent of signing a definitive agreement which would provide 3M with a global license and distribution rights to TSO3's STERIZONE 125L sterilizer including new cycles recently announced by TSO3.
Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
› Verified 5 days ago
| Entity Name | Prime Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427605153 PECOS PAC ID: 1153753520 Enrollment ID: O20191125000404 |
News Archive
Sequencing technology has advanced significantly since the race to sequence the human genome first began. As part of the Teagasc Vision Programme a 'next generation sequencer', the only one of its kind in Ireland, was installed at Teagasc Food Research Centre, Moorepark.
TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that discussions with 3M continue, with the intent of signing a definitive agreement which would provide 3M with a global license and distribution rights to TSO3's STERIZONE 125L sterilizer including new cycles recently announced by TSO3.
Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Garrett James Nelson, MD 9601 Baptist Health Dr Ste 690, Little Rock, AR 72205-6328 Ph: (501) 227-8422 | Garrett James Nelson, MD 9601 Baptist Health Dr Ste 690, Little Rock, AR 72205-6328 Ph: (501) 227-8422 |
News Archive
Sequencing technology has advanced significantly since the race to sequence the human genome first began. As part of the Teagasc Vision Programme a 'next generation sequencer', the only one of its kind in Ireland, was installed at Teagasc Food Research Centre, Moorepark.
TSO3 Inc. ("TSO3") (TSX: TOS), an innovator in low temperature sterilization technology for medical devices in healthcare settings through the use of ozone, today announced that discussions with 3M continue, with the intent of signing a definitive agreement which would provide 3M with a global license and distribution rights to TSO3's STERIZONE 125L sterilizer including new cycles recently announced by TSO3.
Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding vital structures.
OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended March 31, 2010, and presented an update on recent clinical and corporate progress.
› Verified 5 days ago
Dr. Michael Frederick Osleber, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9601 Baptist Health Dr Ste 860, Little Rock, AR 72205 Phone: 501-975-7455 Fax: 501-975-3631 | |
Terri Lynn Martin, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 16115 Saint Vincent Way, Suite 300, Little Rock, AR 72223 Phone: 501-817-3923 Fax: 501-817-3930 | |
Dr. Jacey Tanner Guthrie, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4200 N Rodney Parham Rd Ste 202, Little Rock, AR 72212 Phone: 501-227-4323 Fax: 501-227-4149 | |
Jay Kincannon, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1 Childrens Way # 653, Little Rock, AR 72202 Phone: 501-364-1100 Fax: 501-526-5148 | |
Dr. Lindsay Anne Lipke, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9601 Baptist Health Dr, Suite 690, Little Rock, AR 72205 Phone: 501-227-8422 Fax: 501-537-2399 | |
Dr. Brian Scott Wayne, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 500 S University Ave, Suite 301, Little Rock, AR 72205 Phone: 501-664-4161 |